PBA
ASMB icon

Paradigm Biocapital Advisors’s Assembly Biosciences ASMB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Hold
665,251
– – 0.38% 33
2025
Q4 		$22.6M Buy
+665,251
New +$21.4M 0.58% 27

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paradigm Biocapital Advisors's ASMB Position: Q1 2026 in Review

Paradigm Biocapital Advisors held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 665,251 shares worth $18.5M. The position accounts for 0.38% of the portfolio, ranked #33.

Paradigm Biocapital Advisors first reported a position in ASMB in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.6M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Paradigm Biocapital Advisors held 665,251 shares of Assembly Biosciences worth $18.5M as of Q1 2026.
  • Paradigm Biocapital Advisors left its Assembly Biosciences share count unchanged in Q1 2026.
  • Assembly Biosciences made up 0.38% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #33 holding.
  • Paradigm Biocapital Advisors first reported a position in Assembly Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Paradigm Biocapital Advisors's Assembly Biosciences position peaked at $22.6M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.